j9k1kminby
IV LIGA
Dołączył: 16 Lis 2010
Posty: 112
Przeczytał: 0 tematów
Ostrzeżeń: 0/5
Skąd: England
|
 Wysłany: Śro 10:39, 22 Gru 2010 |
|
|
/>
Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
Report on the pharmaceutical and healthcare industry - Chronic Kidney Disease - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global chronic kidney disease market. This pharma report identifies the key trends shaping and driving the global chronic kidney disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global chronic kidney disease sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalDatas team of industry experts.
Scope
- Annualized global chronic kidney disease market revenues data from 2001 to 2009 [link widoczny dla zalogowanych], forecast forward for 7 years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data split across different phases by mechanism of action and emerging trends. Key classes of mechanism of action phosphate binders, erythropoietin (EPO) activators, nutrition supplements, iron replacement therapy, PTH synthesis inhibitor, Angiotensin Converting Enzyme (ACE) Inhibitor, endothelin antagonist, Angiotensin II Receptor Blocker [link widoczny dla zalogowanych], Antioxidant Inflammation Modulator [link widoczny dla zalogowanych], Direct renin inhibitor, IMPDH Inhibitor, Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor.
- Analysis of the current and future competition in the global chronic kidney disease market. Key market players covered include Reata Pharmaceuticals, Keryx Pharmaceuticals, Cytochroma Inc, Affymax, Ineos Healthcare, Merck & Co Inc, Pfizer, Novartis AG, Amgen and Abbott Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future chronic kidney disease market.
For more information, please visit:
/reports/Chronic-Kidney-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-39189.html
Or email us at [link widoczny dla zalogowanych] or call +919272852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : [link widoczny dla zalogowanych]
Website :
Blog: /
Follow us on twitter: /aarkstoredotcom
相关的主题文章：
[link widoczny dla zalogowanych]
[link widoczny dla zalogowanych]
[link widoczny dla zalogowanych]
Post został pochwalony 0 razy
|
|
